Related Experiment Video
Updated: Jan 23, 2026

Primary Orthotopic Glioma Xenografts Recapitulate Infiltrative Growth and Isocitrate Dehydrogenase I Mutation
Published on: January 14, 2014
Abstract:
Mutant-selective IDH1 inhibitors engage their target in the brain and shrink glioma tumors with an acceptable safety profile, according to phase I trial data on three different drug candidates. However, some clinicians argue the drug strategy might be futile-or even make tumor progression worse.
Insights
Mutant-selective inhibitors targeting isocitrate dehydrogenase 1 (IDH1) show promise in shrinking brain gliomas. Phase I data indicate a good safety profile, though some experts question the strategy's efficacy.
Area of Science:
- Oncology
- Neuro-oncology
- Pharmacology
Background:
- Phase I clinical trials evaluated three novel mutant-selective isocitrate dehydrogenase 1 (IDH1) inhibitors for glioma treatment.
- These inhibitors are designed to target specific IDH1 mutations prevalent in certain gliomas.
Discussion:
- While initial data suggest these IDH1 inhibitors can reach the brain and reduce glioma tumor size, concerns exist regarding their ultimate clinical utility.
- Some clinicians express skepticism about the long-term effectiveness and potential for paradoxical tumor progression.
Key Insights:
- Mutant-selective IDH1 inhibitors demonstrate target engagement within the brain and show tumor shrinkage in glioma patients.
- Phase I trials reported an acceptable safety profile for these investigational drugs.
Outlook:
- Further clinical trials are necessary to validate the efficacy and long-term outcomes of IDH1 inhibitor therapy.
- Investigating the mechanisms behind potential treatment futility or accelerated tumor progression is crucial for optimizing therapeutic strategies.
Related Concept Videos
Mutations
Mutations
Chromosomal Alterations Are Large-Scale Mutations
While point mutations are changes in a single nucleotide in...
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Viral Mutations
Common Ion Effect
Mutation, Gene Flow, and Genetic Drift

